Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review
BackgroundPatients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.943916/full |
| _version_ | 1818490180502290432 |
|---|---|
| author | Jiayi Li Jiayi Li Jiayi Li Xin Zhang Xin Zhang Xin Zhang Xin Zhang Zhuanzhuan Mu Zhuanzhuan Mu Zhuanzhuan Mu Zhuanzhuan Mu Di Sun Di Sun Di Sun Di Sun Yuqing Sun Yuqing Sun Yuqing Sun Yuqing Sun Yansong Lin Yansong Lin Yansong Lin |
| author_facet | Jiayi Li Jiayi Li Jiayi Li Xin Zhang Xin Zhang Xin Zhang Xin Zhang Zhuanzhuan Mu Zhuanzhuan Mu Zhuanzhuan Mu Zhuanzhuan Mu Di Sun Di Sun Di Sun Di Sun Yuqing Sun Yuqing Sun Yuqing Sun Yuqing Sun Yansong Lin Yansong Lin Yansong Lin |
| author_sort | Jiayi Li |
| collection | DOAJ |
| description | BackgroundPatients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of progressive RAIR DTC treated with apatinib plus camrelizumab.Case presentationWe reported a 43-year-old man diagnosed as DTC with metastases in the lungs, the 7th cervical vertebra, and malignant lymph nodes mainly in the mediastinum. While initially showing disease stabilization after giving the first-line multitargeted kinase inhibitor (MKI) therapy, the patient developed progressive disease and was enrolled into a combined therapy with both apatinib and camrelizumab on November 10, 2020. Upon the first 6 months, the combination therapy showed disease control in terms of both stable structural lesions and biochemical thyroglobulin (Tg) level. Six months later, a decrease over the targeted lesions was observed and a partial response (PR) according to RECIST 1.1 criteria was finally achieved upon 12 months’ assessment, followed by the decline in serum Tg level. The main adverse event was occasional diarrhea without treatment interruption.ConclusionWe reported a case with RAIR DTC that benefited from combination immunotherapy, apatinib plus camrelizumab, after resistance from donafenib. We observed a gradually getting better efficacy and a mild and long duration of this combination therapy and hoped to provide a therapeutic choice for these patients. |
| first_indexed | 2024-12-10T17:13:43Z |
| format | Article |
| id | doaj.art-34df042bbcc342e3900d3175b8ffbc4d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-10T17:13:43Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-34df042bbcc342e3900d3175b8ffbc4d2022-12-22T01:40:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.943916943916Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature reviewJiayi Li0Jiayi Li1Jiayi Li2Xin Zhang3Xin Zhang4Xin Zhang5Xin Zhang6Zhuanzhuan Mu7Zhuanzhuan Mu8Zhuanzhuan Mu9Zhuanzhuan Mu10Di Sun11Di Sun12Di Sun13Di Sun14Yuqing Sun15Yuqing Sun16Yuqing Sun17Yuqing Sun18Yansong Lin19Yansong Lin20Yansong Lin21Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, ChinaBeijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, ChinaBeijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, ChinaBeijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, ChinaBeijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, ChinaBeijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, ChinaBeijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaBackgroundPatients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of progressive RAIR DTC treated with apatinib plus camrelizumab.Case presentationWe reported a 43-year-old man diagnosed as DTC with metastases in the lungs, the 7th cervical vertebra, and malignant lymph nodes mainly in the mediastinum. While initially showing disease stabilization after giving the first-line multitargeted kinase inhibitor (MKI) therapy, the patient developed progressive disease and was enrolled into a combined therapy with both apatinib and camrelizumab on November 10, 2020. Upon the first 6 months, the combination therapy showed disease control in terms of both stable structural lesions and biochemical thyroglobulin (Tg) level. Six months later, a decrease over the targeted lesions was observed and a partial response (PR) according to RECIST 1.1 criteria was finally achieved upon 12 months’ assessment, followed by the decline in serum Tg level. The main adverse event was occasional diarrhea without treatment interruption.ConclusionWe reported a case with RAIR DTC that benefited from combination immunotherapy, apatinib plus camrelizumab, after resistance from donafenib. We observed a gradually getting better efficacy and a mild and long duration of this combination therapy and hoped to provide a therapeutic choice for these patients.https://www.frontiersin.org/articles/10.3389/fimmu.2022.943916/fullradioactive iodine refractorydifferentiated thyroid cancercombination immunotherapymultitargeted kinase inhibitors plus PD-1/PD-L1 inhibitors therapyapatinib plus camrelizumab treatment |
| spellingShingle | Jiayi Li Jiayi Li Jiayi Li Xin Zhang Xin Zhang Xin Zhang Xin Zhang Zhuanzhuan Mu Zhuanzhuan Mu Zhuanzhuan Mu Zhuanzhuan Mu Di Sun Di Sun Di Sun Di Sun Yuqing Sun Yuqing Sun Yuqing Sun Yuqing Sun Yansong Lin Yansong Lin Yansong Lin Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review Frontiers in Immunology radioactive iodine refractory differentiated thyroid cancer combination immunotherapy multitargeted kinase inhibitors plus PD-1/PD-L1 inhibitors therapy apatinib plus camrelizumab treatment |
| title | Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review |
| title_full | Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review |
| title_fullStr | Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review |
| title_full_unstemmed | Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review |
| title_short | Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review |
| title_sort | response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti angiogenic therapy a case report and literature review |
| topic | radioactive iodine refractory differentiated thyroid cancer combination immunotherapy multitargeted kinase inhibitors plus PD-1/PD-L1 inhibitors therapy apatinib plus camrelizumab treatment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.943916/full |
| work_keys_str_mv | AT jiayili responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT jiayili responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT jiayili responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT xinzhang responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT xinzhang responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT xinzhang responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT xinzhang responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT zhuanzhuanmu responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT zhuanzhuanmu responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT zhuanzhuanmu responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT zhuanzhuanmu responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT disun responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT disun responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT disun responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT disun responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT yuqingsun responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT yuqingsun responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT yuqingsun responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT yuqingsun responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT yansonglin responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT yansonglin responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview AT yansonglin responsetoapatinibandcamrelizumabcombinedtreatmentinaradioiodinerefractorydifferentiatedthyroidcancerpatientresistanttopriorantiangiogenictherapyacasereportandliteraturereview |